Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells

1.

DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64(1):52–62. doi:10.3322/caac.21203 PubMedCrossRef

2.

DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64(4):252–271. doi:10.3322/caac.21235 PubMedCrossRef

3.

Fidler IJ, Gersten DM, Hart IR (1978) The biology of cancer invasion and metastasis. Adv Cancer Res 28:149–250PubMedCrossRef

4.

Coghlin C, Murray GI (2010) Current and emerging concepts in tumour metastasis. J Pathol 222(1):1–15. doi:10.1002/path.2727 PubMedCrossRef

5.

Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56. doi:10.1038/3506501635065016 PubMedCrossRef

6.

Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F (2013) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi7–v23. doi:10.1093/annonc/mdt284 PubMedCrossRef

7.

Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ, Buchholz TA, Giordano SH (2012) Hazard of recurrence among women after primary breast cancer treatment–a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomark Prev 21(5):800–809CrossRef

8.

Kayser K, Burkhardt HU (1980) Crude and age-specific incidence of cancer of the stomach, colon, breast, and lung ascertained by autopsy frequency in the Heidelberg area from 1900 to 1975. J Cancer Res Clin Oncol 96(1):11–25PubMedCrossRef

9.

Allison KH, Fligner CL, Parks WT (2004) Radiographically occult, diffuse intrasinusoidal hepatic metastases from primary breast carcinomas: a clinicopathologic study of 3 autopsy cases. Arch Pathol Lab Med 128(12):1418–1423. doi:10.1043/1543-2165(2004)128<1418:rodihm>2.0.co;2 PubMed

10.

Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97(26):14608–14613. doi:10.1073/pnas.97.26.1460897/26/14608 PubMedPubMedCentralCrossRef

11.

Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153(3):865–873. doi:10.1016/S0002-9440(10)65628-3 PubMedPubMedCentralCrossRef

12.

Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8):563–572. doi:10.1038/nrc865 PubMedCrossRef

13.

Makki J (2015) Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol 8:23–31. doi:10.4137/CPath PubMedPubMedCentralCrossRef

14.

Toss A, Cristofanilli M (2015) Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res 17:60. doi:10.1186/s13058-015-0560-9 PubMedPubMedCentralCrossRef

15.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–527PubMedPubMedCentralCrossRef

16.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093 PubMedCrossRef

17.

van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009. doi:10.1056/NEJMoa021967 PubMedCrossRef

18.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68. doi:10.1186/bcr2635 PubMedPubMedCentralCrossRef

19.

Johann DJ, Rodriguez-Canales J, Mukherjee S, Prieto DA, Hanson JC, Emmert-Buck M, Blonder J (2009) Approaching solid tumor heterogeneity on a cellular basis by tissue proteomics using laser capture microdissection and biological mass spectrometry. J Proteome Res 8(5):2310–2318. doi:10.1021/pr8009403 PubMedPubMedCentralCrossRef

20.

Bateman NW, Sun M, Bhargava R, Hood BL, Darfler MM, Kovatich AJ, Hooke JA, Krizman DB, Conrads TP (2011) Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues. J Proteome Res 10(3):1323–1332. doi:10.1021/pr101073s PubMedCrossRef

21.

Morrison BJ, Hastie ML, Grewal YS, Bruce ZC, Schmidt C, Reynolds BA, Gorman JJ, Lopez JA (2012) Proteomic comparison of mcf-7 tumoursphere and monolayer cultures. PLoS One 7(12):e52692. doi:10.1371/journal.pone.0052692 PubMedPubMedCentralCrossRef

22.

Mego M, Mani SA, Cristofanilli M (2010) Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat Rev Clin Oncol. doi:10.1038/nrclinonc.2010.171 PubMed

23.

Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98(24):1777–1785. doi:10.1093/jnci/djj495 PubMedCrossRef

24.

Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM (1996) Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 87(3):1097–1103PubMed

25.

Sottoriva A, Kang H, Ma Z, Graham TA, Salomon MP, Zhao J, Marjoram P, Siegmund K, Press MF, Shibata D, Curtis C (2015) A Big Bang model of human colorectal tumor growth. Nat Genet 47(3):209–216. doi:10.1038/ng.3214 PubMedPubMedCentralCrossRef

26.

Friedl P, Alexander S (2011) Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147(5):992–1009. doi:10.1016/j.cell.2011.11.016 PubMedCrossRef

27.

Seyfried TN, Huysentruyt LC (2013) On the origin of cancer metastasis. Crit Rev Oncog 18(1–2):43–73PubMedPubMedCentralCrossRef

28.

Sleeman JP, Christofori G, Fodde R, Collard JG, Berx G, Decraene C, Ruegg C (2012) Concepts of metastasis in flux: the stromal progression model. Semin Cancer Biol 22(3):174–186. doi:10.1016/j.semcancer.2012.02.007 PubMedCrossRef

29.

Terranova VP, Hic S, Diflorio RM, Lyall RM (1986) Tumor cell metastasis. Crit Rev Oncol/Hematol 5(2):87–114CrossRef

30.

Ashworth TR (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust 14:146–149

31.

Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133(3421):571–573. doi:10.1016/S0140-6736(00)49915-0 CrossRef

32.

Fidler IJ, Poste G (2008) The “seed and soil” hypothesis revisited. Lancet Oncol 9(8):808. doi:10.1016/S1470-2045(08)70201-8 PubMedCrossRef

33.

Ribatti D, Mangialardi G, Vacca A (2006) Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination. Clin Exp Med 6(4):145–149. doi:10.1007/s10238-006-0117-4 PubMedCrossRef

34.

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584–593. doi:10.1038/nrc867 PubMedCrossRef

35.

Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, Wang D, Holen I, Done SJ, Clemons M (2009) Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis. doi:10.1007/s10585-009-9284-5 PubMed

36.

Dupont VN, Gentien D, Oberkampf M, De Rycke Y, Blin N (2007) A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. Int J Cancer 121(5):1036–1046PubMedCrossRef

37.

Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13(1):58–68PubMedCrossRef

38.

Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827. doi:10.1038/nature04186 PubMedPubMedCentralCrossRef

39.

Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 66(23):11089–11093. doi:10.1158/0008-5472.CAN-06-2407 PubMedPubMedCentralCrossRef

40.

Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, Georgoulias V, Mavroudis D, Agelaki S (2009) Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 11(6):R84. doi:10.1186/bcr2452 PubMedPubMedCentralCrossRef

41.

Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S (2011) Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 13(3):R59. doi:10.1186/bcr2896 PubMedPubMedCentralCrossRef

42.

Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Haffty BG, Pantel K, Massague J, Kang Y (2011) VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20(6):701–714. doi:10.1016/j.ccr.2011.11.002 PubMedPubMedCentralCrossRef

43.

Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, Port JL, Stiles B, Sukumar S, Altorki NK, Rafii S, Mittal V (2012) Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res 72(6):1384–1394. doi:10.1158/0008-5472.CAN-11-2905 PubMedCrossRef

44.

Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J (2002) Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8(7):2073–2084PubMed

45.

Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massague J (2009) Tumor self-seeding by circulating cancer cells. Cell 139(7):1315–1326. doi:10.1016/j.cell.2009.11.025 PubMedPubMedCentralCrossRef

46.

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802PubMedCrossRef

47.

Dondossola E, Crippa L, Colombo B, Ferrero E, Corti A (2011) Chromogranin A regulates tumor self-seeding and dissemination. Cancer Res. doi:10.1158/0008-5472.CAN-11-2944

48.

Zhang Y, Ma Q, Liu T, Ke S, Jiang K, Wen Y, Ma B, Zhou Y, Fan Q, Qiu X (2014) Tumor self-seeding by circulating tumor cells in nude mouse models of human osteosarcoma and a preliminary study of its mechanisms. J Cancer Res Clin Oncol 140(2):329–340. doi:10.1007/s00432-013-1561-7 PubMedCrossRef

49.

Hahnfeldt P (2010) Significance of tumor self-seeding as an augmentation to the classic metastasis paradigm. Future Oncol 6(5):681–685. doi:10.2217/fon.10.43 PubMedCrossRef

50.

Aguirre-Ghiso JA (2010) On the theory of tumor self-seeding: implications for metastasis progression in humans. Breast Cancer Res 12(2):304. doi:10.1186/bcr2561 PubMedPubMedCentralCrossRef

51.

Norton L (2011) Tumor self-seeding in breast cancer. Clin Adv Hematol Oncol 9(7):541–542PubMed

52.

Comen E, Norton L, Massague J (2011) Clinical implications of cancer self-seeding. Nat Rev Clin Oncol 8(6):369–377. doi:10.1038/nrclinonc.2011.64 PubMed

53.

Comen E, Norton L (2012) Self-seeding in cancer. Recent Results Cancer Res 195:13–23. doi:10.1007/978-3-642-28160-0_2 PubMedCrossRef

54.

Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10(2):R25. doi:10.1186/bcr1982 PubMedPubMedCentralCrossRef

55.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672–679. doi:10.1093/jnci/djn123 PubMedCrossRef

56.

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33):13820–13825. doi:10.1073/pnas.0905718106 PubMedPubMedCentralCrossRef

57.

Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, Pajonk F (2010) Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res 12(1):R13. doi:10.1186/bcr2479 PubMedPubMedCentralCrossRef

58.

Zhan JF, Chen LH, Yuan YW, Xie GZ, Sun AM, Liu Y, Chen ZX (2011) STAT1 promotes radioresistance of CD44(+)/CD24(−/low) cells in breast cancer. Exp Biol Med (Maywood, NJ) 236(4):418–422. doi:10.1258/ebm.2011.010287 CrossRef

59.

Van Phuc P, Nhan PL, Nhung TH, Tam NT, Hoang NM, Tue VG, Thuy DT, Ngoc PK (2011) Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. OncoTargets Ther 4:71–78. doi:10.2147/ott.s21431 CrossRef

60.

Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219–234. doi:10.1038/nrd1984 PubMedCrossRef

61.

Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A (2004) ABCG2—a transporter for all seasons. FEBS Lett 567(1):116–120. doi:10.1016/j.febslet.2004.03.123 PubMedCrossRef

62.

Shay JW, Gazdar AF (1997) Telomerase in the early detection of cancer. J Clin Pathol 50(2):106–109PubMedPubMedCentralCrossRef

63.

Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266(5186):807–810PubMedCrossRef

64.

Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109(3):335–346PubMedCrossRef

65.

Borst P, Jonkers J, Rottenberg S (2007) What makes tumors multidrug resistant? Cell Cycle (Georgetown, Tex) 6(22):2782–2787CrossRef

66.

Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP, Jonkers J, Borst P (2007) Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 104(29):12117–12122. doi:10.1073/pnas.0702955104 PubMedPubMedCentralCrossRef

67.

Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM (2007) Chemotherapy dose–response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 33(2):101–137. doi:10.1016/j.ctrv.2006.12.002 PubMedCrossRef

68.

Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972–2977. doi:10.1002/cncr.11436 PubMedCrossRef

69.

Olson P, Hanahan D (2009) Cancer. Breaching the cancer fortress. Science 324(5933):1400–1401. doi:10.1126/science.1175940 PubMedCrossRef

70.

Borst P (2012) Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2(5):120066. doi:10.1098/rsob.120066 PubMedPubMedCentralCrossRef

71.

Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141(1):69–80. doi:10.1016/j.cell.2010.02.027 PubMedPubMedCentralCrossRef

72.

Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178–196. doi:10.1038/nrm3758 PubMedPubMedCentralCrossRef

73.

Knights AJ, Funnell AP, Crossley M, Pearson RC (2012) Holding tight: cell junctions and cancer spread. Trends Cancer Res 8:61–69PubMedPubMedCentral

74.

Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119(6):1417–1419. doi:10.1172/JCI39675 PubMedPubMedCentralCrossRef

75.

Boyer B, Valles AM, Edme N (2000) Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 60(8):1091–1099PubMedCrossRef

76.

Tomaskovic-Crook E, Thompson EW, Thiery JP (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11(6):213. doi:10.1186/bcr2416 PubMedPubMedCentralCrossRef

77.

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142. doi:10.1038/nrm1835 PubMedCrossRef

78.

Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M (2010) Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101(2):293–299. doi:10.1111/j.1349-7006.2009.01419.x PubMedCrossRef

79.

Pokutta S, Drees F, Yamada S, Nelson WJ, Weis WI (2008) Biochemical and structural analysis of alpha-catenin in cell-cell contacts. Biochem Soc Trans 36(Pt 2):141–147. doi:10.1042/bst0360141 PubMedPubMedCentralCrossRef

80.

Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253(2):180–204PubMedCrossRef

81.

Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673–687PubMedCrossRef

82.

Ffrench-Constant C, Colognato H (2004) Integrins: versatile integrators of extracellular signals. Trends Cell Biol 14(12):678–686. doi:10.1016/j.tcb.2004.10.005 PubMedCrossRef

83.

Werb Z (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 91(4):439–442PubMedCrossRef

84.

Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M (2004) Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 91(3):450–456. doi:10.1160/TH03-12-0798 PubMed

85.

Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA (2004) Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5(5):348–352PubMedCrossRef

86.

Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4):645–659. doi:10.1016/j.cell.2009.06.034 PubMedPubMedCentralCrossRef

87.

Argast GM, Mercado P, Mulford IJ, O’Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL (2011) Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs 193(1–2):114–132. doi:10.1159/000320179 PubMedCrossRef

88.

Argast GM, Krueger JS, Thomson S, Sujka-Kwok I, Carey K, Silva S, O’Connor M, Mercado P, Mulford IJ, Young GD, Sennello R, Wild R, Pachter JA, Kan JL, Haley J, Rosenfeld-Franklin M, Epstein DM (2011) Inducible expression of TGFbeta, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp Metastasis 28(7):593–614. doi:10.1007/s10585-011-9394-8 PubMedCrossRef

89.

Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ, Brandt B, Boecker W, Buerger H (2005) The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 206(4):451–457. doi:10.1002/path.1797 PubMedCrossRef

90.

Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer–observations in vitro and in vivo. Cells Tissues Organs 185(1–3):191–203. doi:10.1159/000101320 PubMedCrossRef

91.

Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68(4):989–997. doi:10.1158/0008-5472.CAN-07-2017 PubMedCrossRef

92.

Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11(22):8006–8014. doi:10.1158/1078-0432.CCR-05-0632 PubMedCrossRef

93.

Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Lakhani SR, Palacios J, Rakha E, Richardson AL, Schmitt FC, Tan PH, Tse GM, Vincent-Salomon A, Ellis IO, Badve S, Reis-Filho JS (2013) Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol 37(7):e1–e11. doi:10.1097/PAS.0b013e3182918a2b PubMedCrossRef

94.

McCart Reed AE, Kutasovic JR, Vargas AC, Jayanthan J, Al-Murrani A, Reid LE, Chambers R, Silva LD, Melville L, Evans E, Porter A, Papadimos D, Thompson EW, Lakhani SR, Simpson PT (2015) An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas. J Pathol. doi:10.1002/path.4668 PubMed

95.

Agiostratidou G, Li M, Suyama K, Badano I, Keren R, Chung S, Anzovino A, Hulit J, Qian B, Bouzahzah B, Eugenin E, Loudig O, Phillips GR, Locker J, Hazan RB (2009) Loss of retinal cadherin facilitates mammary tumor progression and metastasis. Cancer Res 69(12):5030–5038. doi:10.1158/0008-5472.CAN-08-4007 PubMedPubMedCentralCrossRef

96.

Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251(5000):1451–1455PubMedCrossRef

97.

Geiger B, Ayalon O (1992) Cadherins. Annu Rev Cell Biol 8:307–332. doi:10.1146/annurev.cb.08.110192.001515 PubMedCrossRef

98.

Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172(7):973–981PubMedPubMedCentralCrossRef

99.

Muller V, Alix-Panabieres C, Pantel K (2010) Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer (Oxford, England: 1990) 46(7):1189–1197. doi:10.1016/j.ejca.2010.02.038 CrossRef

100.

Bonnomet A, Brysse A, Tachtsidis A, Waltham M, Thompson EW, Polette M, Gilles C (2010) Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 15(2):261–273. doi:10.1007/s10911-010-9174-0 PubMedCrossRef

101.

Funke I, Fries S, Rolle M, Heiss MM, Untch M, Bohmert H, Schildberg FW, Jauch KW (1996) Comparative analyses of bone marrow micrometastases in breast and gastric cancer. Int J Cancer 65(6):755–761. doi:10.1002/(sici)1097-0215(19960315)65:6<755:aid-ijc8>3.0.co;2-y PubMedCrossRef

102.

Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, Zahn R, Riethmuller G, Pantel K (1999) Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 59(1):241–248PubMed

103.

Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL (2007) Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 13(17):5001–5009. doi:10.1158/1078-0432.CCR-07-0024 PubMedPubMedCentralCrossRef

104.

Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M (2011) Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer 129(2):417–423. doi:10.1002/ijc.25690 PubMedCrossRef

105.

Bednarz N, Eltze E, Semjonow A, Rink M, Andreas A, Mulder L, Hannemann J, Fisch M, Pantel K, Weier HU, Bielawski KP, Brandt B (2010) BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res 16(13):3340–3348. doi:10.1158/1078-0432.CCR-10-0150 PubMedPubMedCentralCrossRef

106.

Domagala W, Lasota J, Dukowicz A, Markiewski M, Striker G, Weber K, Osborn M (1990) Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol 137(6):1299–1304PubMedPubMedCentral

107.

Bartkowiak K, Effenberger KE, Harder S, Andreas A, Buck F, Peter-Katalinic J, Pantel K, Brandt BH (2010) Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J Proteome Res 9(6):3158–3168. doi:10.1021/pr100039d PubMedCrossRef

108.

Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F (2011) Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 105(9):1338–1341. doi:10.1038/bjc.2011.405 PubMedPubMedCentralCrossRef

109.

Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noel A, Foidart JM, Birembaut P, Polette M, Gilles C (2011) A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene. doi:10.1038/onc.2011.540 PubMed

110.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988. doi:10.1073/pnas.0530291100 PubMedPubMedCentralCrossRef

111.

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. doi:10.1016/j.stem.2007.08.014 PubMedPubMedCentralCrossRef

112.

Ribeiro AS, Paredes J (2014) P-cadherin linking breast cancer stem cells and invasion: a promising marker to identify an “Intermediate/Metastable” EMT state. Front Oncol 4:371. doi:10.3389/fonc.2014.00371 PubMedCrossRef

113.

Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3(8):e2888. doi:10.1371/journal.pone.0002888 PubMedPubMedCentralCrossRef

114.

Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11(4):R46. doi:10.1186/bcr2333 PubMedPubMedCentralCrossRef

115.

Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, Wong YC (2004) Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23(2):474–482. doi:10.1038/sj.onc.1207128 PubMedCrossRef

116.

Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, Gazzaniga P (2011) Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat. doi:10.1007/s10549-011-1373-x PubMed

117.

Qi X, Yang X, Fan L, Zhang Y, Zhang F, Jiang J (2010) Association between the spread of circulating tumor cells and breast cancer subtypes. Breast Cancer Res 12(3):402. doi:10.1186/bcr2582 PubMedPubMedCentralCrossRef

118.

Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, Weinberg RA, Neve RM, Lenburg ME, Thompson EW (2010) Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/−) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 15(2):235–252. doi:10.1007/s10911-010-9175-z PubMedCrossRef

119.

Thompson EW, Haviv I (2011) The social aspects of EMT-MET plasticity. Nat Med 17(9):1048–1049. doi:10.1038/nm.2437 PubMedCrossRef

120.

Chao YL, Shepard CR, Wells A (2010) Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 9:179. doi:10.1186/1476-4598-9-179 PubMedPubMedCentralCrossRef

121.

Orsulic S, Huber O, Aberle H, Arnold S, Kemler R (1999) E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci 112(Pt 8):1237–1245PubMed

122.

Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, MacBeath G (2014) A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell 159(4):844–856. doi:10.1016/j.cell.2014.10.032 PubMedPubMedCentralCrossRef

123.

Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66(23):11271–11278. doi:10.1158/0008-5472.CAN-06-2044 PubMedCrossRef

124.

Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW (2007) Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 213(2):374–383PubMedCrossRef

125.

van der Pluijm G (2011) Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 48(1):37–43. doi:10.1016/j.bone.2010.07.023 PubMedCrossRef

126.

Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA (2011) Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9(8):997–1007. doi:10.1158/1541-7786.MCR-10-0490 PubMedPubMedCentralCrossRef

127.

Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J (2012) Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22(6):725–736. doi:10.1016/j.ccr.2012.09.022 PubMedPubMedCentralCrossRef

128.

Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA (2012) Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22(6):709–724. doi:10.1016/j.ccr.2012.10.012 PubMedCrossRef

129.

Huang RY, Kuay KT, Tan TZ, Asad M, Tang HM, Chun Ng AH, Ye J, Chung VY, Thiery JP (2015) Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120). Oncotarget 6:22098PubMedPubMedCentralCrossRef

130.

Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, Thiery JP (2014) Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med 6(10):1279–1293. doi:10.15252/emmm.201404208 PubMedPubMedCentralCrossRef

131.

van Denderen BJ, Thompson EW (2013) Cancer: the to and fro of tumour spread. Nature 493(7433):487–488. doi:10.1038/493487a PubMedCrossRef

132.

Barriere G, Riouallon A, Renaudie J, Tartary M, Rigaud M (2012) Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer 12:114. doi:10.1186/1471-2407-12-114 PubMedPubMedCentralCrossRef

133.

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584. doi:10.1126/science.1228522 PubMedPubMedCentralCrossRef

134.

Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, Yang D, Deng H, Yang N, Xu J (2015) Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One 10(4):e0123976. doi:10.1371/journal.pone.0123976 PubMedPubMedCentralCrossRef

135.

Islam F, Qiao B, Smith RA, Gopalan V, Lam AK (2015) Cancer stem cell: fundamental experimental pathological concepts and updates. Exp Mol Pathol 98(2):184–191. doi:10.1016/j.yexmp.2015.02.002 PubMedCrossRef

136.

Cabrera MC, Hollingsworth RE, Hurt EM (2015) Cancer stem cell plasticity and tumor hierarchy. World J Stem Cells 7(1):27–36. doi:10.4252/wjsc.v7.i1.27 PubMedPubMedCentralCrossRef

137.

Pretlow TG, Schwartz S, Giaconia JM, Wright AL, Grimm HA, Edgehouse NL, Murphy JR, Markowitz SD, Jamison JM, Summers JL, Hamlin CR, MacLennan GT, Resnick MI, Pretlow TP, Connell CF (2000) Prostate cancer and other xenografts from cells in peripheral blood of patients. Cancer Res 60(15):4033–4036PubMed

138.

Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101(25):9393–9398. doi:10.1073/pnas.0402993101 PubMedPubMedCentralCrossRef

139.

Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V (2008) Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 10(5):R80. doi:10.1186/bcr2149 PubMedPubMedCentralCrossRef

140.

Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bauerle T, Wallwiener M, Holland-Letz T, Hofner T, Sprick M, Scharpff M, Marme F, Sinn HP, Pantel K, Weichert W, Trumpp A (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544. doi:10.1038/nbt.2576 PubMedCrossRef

141.

Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K, Pepper SD, Nonaka D, Greystoke A, Kelly P, Bola B, Krebs MG, Antonello J, Ayub M, Faulkner S, Priest L, Carter L, Tate C, Miller CJ, Blackhall F, Brady G, Dive C (2014) Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 20(8):897–903. doi:10.1038/nm.3600 PubMedCrossRef

142.

Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M, Maheswaran S, Haber DA (2014) Cancer therapy Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345(6193):216–220. doi:10.1126/science.1253533 PubMedPubMedCentralCrossRef

143.

Husemann Y, Klein CA (2009) The analysis of metastasis in transgenic mouse models. Transgenic Res 18(1):1–5. doi:10.1007/s11248-008-9225-0 PubMedCrossRef

144.

Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A (2010) Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 116(14):3330–3337. doi:10.1002/cncr.25145 PubMedCrossRef

145.

Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9(4):302–312. doi:10.1038/nrc2627 PubMedCrossRef

146.

Komori J, Boone L, DeWard A, Hoppo T, Lagasse E (2012) The mouse lymph node as an ectopic transplantation site for multiple tissues. Nat Biotechnol 30(10):976–983. doi:10.1038/nbt.2379 PubMedPubMedCentralCrossRef

147.

Podsypanina K, Du YC, Jechlinger M, Beverly LJ, Hambardzumyan D, Varmus H (2008) Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321(5897):1841–1844. doi:10.1126/science.1161621 PubMedPubMedCentralCrossRef

148.

Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148(1–2):349–361. doi:10.1016/j.cell.2011.11.025 PubMedPubMedCentralCrossRef

149.

Townson JL, Chambers AF (2006) Dormancy of solitary metastatic cells. Cell Cycle (Georgetown, Tex) 5(16):1744–1750CrossRef

150.

Wikman H, Vessella R, Pantel K (2008) Cancer micrometastasis and tumour dormancy. Apmis 116(7–8):754–770PubMedCrossRef

151.

Paez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ (2012) Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 18(3):645–653. doi:10.1158/1078-0432.ccr-11-2186 PubMedCrossRef

152.

Mitra A, Mishra L, Li S (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6(13):10697–10711. doi:10.18632/oncotarget.4037 PubMedPubMedCentralCrossRef

153.

Raviraj V, Zhang H, Chien HY, Cole L, Thompson EW, Soon L (2012) Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas. Clin Exp Metastasis 29(3):273–292. doi:10.1007/s10585-011-9450-4 PubMedCrossRef

154.

Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100(13):7737–7742. doi:10.1073/pnas.1331931100 PubMedPubMedCentralCrossRef

155.

Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J (1997) Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57(8):1597–1604PubMed

156.

van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536. doi:10.1038/415530a CrossRef

157.

Weigelt B, van’t Veer LJ (2004) Hard-wired genotype in metastatic breast cancer. Cell Cycle (Georgetown, Tex) 3(6):756–757CrossRef

158.

Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368(13):1199–1209. doi:10.1056/NEJMoa1213261 PubMedCrossRef

159.

Cunha PO, Ornstein M, Jones JL (2010) Progression of ductal carcinoma in situ from the pathological perspective. Breast Care (Basel) 5(4):233–239. doi:10.1159/000319625 CrossRef

160.

Sanger N, Effenberger KE, Riethdorf S, Van Haasteren V, Gauwerky J, Wiegratz I, Strebhardt K, Kaufmann M, Pantel K (2011) Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer 129(10):2522–2526. doi:10.1002/ijc.25895 PubMedCrossRef

161.

Kelly TA, Kim JA, Patrick R, Grundfest S, Crowe JP (2003) Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg 186(4):368–370PubMedCrossRef

162.

Banys M, Gruber I, Krawczyk N, Becker S, Kurth R, Wallwiener D, Jakubowska J, Hoffmann J, Rothmund R, Staebler A, Fehm T (2012) Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast. Breast Cancer Res Treat 131(3):801–808. doi:10.1007/s10549-011-1478-2 PubMedCrossRef

163.

Prendeville S, Ryan C, Feeley L, O’Connell F, Browne TJ, O’Sullivan MJ, Bennett MW (2015) Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. Breast (Edinburgh, Scotland) 24(3):197–200. doi:10.1016/j.breast.2015.01.004 CrossRef

164.

Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ (Clinical research ed) 351:h4901. doi:10.1136/bmj.h4901

165.

Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737PubMedCrossRef

166.

Cherciu I, Barbalan A, Pirici D, Margaritescu C, Saftoiu A (2014) Stem cells, colorectal cancer and cancer stem cell markers correlations. Curr Health Sci J 40(3):153–161. doi:10.12865/chsj.40.03.01 PubMedPubMedCentral

167.

Pointer KB, Clark PA, Zorniak M, Alrfaei BM, Kuo JS (2014) Glioblastoma cancer stem cells: biomarker and therapeutic advances. Neurochem Int 71:1–7. doi:10.1016/j.neuint.2014.03.005 PubMedPubMedCentralCrossRef

168.

Kerr CL, Hussain A (2014) Regulators of prostate cancer stem cells. Curr Opin Oncol 26(3):328–333. doi:10.1097/cco.0000000000000080 PubMedCrossRef

169.

Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus NH, Nieva J, Kuhn P (2007) Case study of the morphologic variation of circulating tumor cells. Hum Pathol 38(3):514–519. doi:10.1016/j.humpath.2006.08.027 PubMedCrossRef

170.

Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS (2012) Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 7(5):e33788. doi:10.1371/journal.pone.0033788 PubMedPubMedCentralCrossRef

171.

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12(19):5615–5621PubMedCrossRef

172.

Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H (2005) Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11(3):1154–1159PubMed

173.

Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ (2004) CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64(16):5702–5711. doi:10.1158/0008-5472.CAN-04-0389 PubMedCrossRef

174.

Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F (2005) Cancer stem cell characteristics in retinoblastoma. Mol Vis 11:729–737PubMed

175.

Douville J, Beaulieu R, Balicki D (2009) ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18(1):17–25. doi:10.1089/scd.2008.0055 PubMedCrossRef

176.

Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V (2009) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. doi:10.1016/j.canlet.2009.06.027 PubMed

177.

Balic M, Rapp N, Stanzer S, Lin H, Strutz J, Szkandera J, Daidone MG, Samonigg H, Cote RJ, Dandachi N (2011) Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl Immunohistochem Mol Morphol 19(1):33–40. doi:10.1097/PAI.0b013e3181ebf4e8 PubMedCrossRef

178.

Ahmed N, Abubaker K, Findlay J, Quinn M (2010) Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 10:268–278PubMedCrossRef

179.

Al Saleh S, Sharaf LH, Luqmani YA (2011) Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 38(5):1197–1217. doi:10.3892/ijo.2011.942 PubMed

180.

Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116–4124. doi:10.1158/0008-5472.CAN-08-3441 PubMedPubMedCentralCrossRef

181.

Patel P, Chen EI (2012) Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne) 3:125. doi:10.3389/fendo.2012.00125

182.

Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: mirage or reality? Nat Med 15(9):1010–1012. doi:10.1038/nm0909-1010 PubMedCrossRef

183.

Rowan K (2009) Are cancer stem cells real? After four decades, debate still simmers. J Natl Cancer Inst 101(8):546–547PubMedCrossRef

184.

Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, Weinberg RA (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 108(19):7950–7955. doi:10.1073/pnas.1102454108 PubMedPubMedCentralCrossRef

185.

Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D’Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, Birnbaum D, Wong ST, Zhan M, Chang JC, Wicha MS (2014) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep 2(1):78–91. doi:10.1016/j.stemcr.2013.11.009 CrossRef

186.

Sarrio D, Franklin CK, Mackay A, Reis-Filho JS, Isacke CM (2012) Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 30(2):292–303. doi:10.1002/stem.791 PubMedCrossRef

187.

Adams JM, Strasser A (2008) Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res 68(11):4018–4021. doi:10.1158/0008-5472.CAN-07-6334 PubMedCrossRef

188.

Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A (2007) Tumor growth need not be driven by rare cancer stem cells. Science 317(5836):337. doi:10.1126/science.1142596 PubMedCrossRef

189.

Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456(7222):593–598. doi:10.1038/nature07567 PubMedPubMedCentralCrossRef

190.

Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18(5):510–523. doi:10.1016/j.ccr.2010.10.012 PubMedPubMedCentralCrossRef

191.

Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Janne PA, Kuang Y, Yanagita M, Wang L, Berkowitz JA, Distel RJ, Cayre YE (2011) A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res 31(2):427–441PubMed

192.

Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, Andre F, Fizazi K, Soria JC, Vielh P (2011) A direct comparison of Cell Search and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 105(6):847–853. doi:10.1038/bjc.2011.294 PubMedPubMedCentralCrossRef

193.

Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y (2011) Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol 137(8):1151–1173. doi:10.1007/s00432-011-0988-y PubMedCrossRef

194.

Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10(24):8152–8162. doi:10.1158/1078-0432.CCR-04-1110 PubMedCrossRef

195.

Hofman VJ, Ilie MI, Bonnetaud C, Selva E, Long E, Molina T, Vignaud JM, Flejou JF, Lantuejoul S, Piaton E, Butori C, Mourad N, Poudenx M, Bahadoran P, Sibon S, Guevara N, Santini J, Venissac N, Mouroux J, Vielh P, Hofman PM (2011) Cytopathologic detection of circulating tumor cells using the isolation by size of epithelial tumor cell method: promises and pitfalls. Am J Clin Pathol 135(1):146–156. doi:10.1309/AJCP9X8OZBEIQVVI PubMedCrossRef

196.

Vincent-Salomon A, Bidard FC, Pierga JY (2008) Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. J Clin Pathol 61(5):570–576PubMedCrossRef

197.

Krawczyk N, Banys M, Neubauer H, Solomayer EF, Gall C, Hahn M, Becker S, Bachmann R, Wallwiener D, Fehm T (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 29(10):4019–4024PubMed

198.

Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P, Bruce R, Nieva J, Kuhn P (2009) Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol 2010:861341. doi:10.1155/2010/861341

199.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield, Hayes DF, Bast RC Jr, American Society of Clinical O (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312. doi:10.1200/JCO.2007.14.2364 PubMedCrossRef

200.

Cristofanilli M, Mendelsohn J (2006) Circulating tumor cells in breast cancer: advanced tools for “tailored” therapy? Proc Natl Acad Sci USA 103(46):17073–17074PubMedPubMedCentralCrossRef

201.

Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabieres C, Janni W, Messina C, Paoletti C, Muller V, Hayes DF, Piccart M, Pierga JY (2013) Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 32(1–2):179–188. doi:10.1007/s10555-012-9398-0 PubMedCrossRef

202.

Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O’Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32(31):3483–3489. doi:10.1200/JCO.2014.56.2561 PubMedPubMedCentralCrossRef

203.

Helissey C, Berger F, Cottu P, Dieras V, Mignot L, Servois V, Bouleuc C, Asselain B, Pelissier S, Vaucher I, Pierga JY, Bidard FC (2015) Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. Cancer Lett 360(2):213–218. doi:10.1016/j.canlet.2015.02.010 PubMedCrossRef

204.

Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329–340. doi:10.1038/nrc2375 PubMedCrossRef

205.

Pantel K, Alix-Panabieres C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16(9):398–406. doi:10.1016/j.molmed.2010.07.001 PubMedCrossRef

206.

Gerges N, Rak J, Jabado N (2010) New technologies for the detection of circulating tumour cells. Br Med Bull. doi:10.1093/bmb/ldq011 PubMed

207.

Hughes AD, King MR (2011) Nanobiotechnology for the capture and manipulation of circulating tumor cells. Wiley Interdiscip Rev Nanomed Nanobiotechnol. doi:10.1002/wnan.168 PubMed

208.

Mostert B, Sleijfer S, Foekens JA, Gratama JW (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35(5):463–474. doi:10.1016/j.ctrv.2009.03.004 PubMedCrossRef

209.

Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K (1999) Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 17(1):19–24PubMed

210.

Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H et al (1987) Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 84(23):8672–8676PubMedPubMedCentralCrossRef

211.

Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, Timmermans AM, Foekens R, Martens JW, Gratama JW, Foekens JA, Sleijfer S (2010) Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat. doi:10.1007/s10549-010-0879-y PubMed

212.

Baker MK, Mikhitarian K, Osta W, Callahan K, Hoda R, Brescia F, Kneuper-Hall R, Mitas M, Cole DJ, Gillanders WE (2003) Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clin Cancer Res 9(13):4865–4871PubMed

213.

Dardaei L, Shahsavani R, Ghavamzadeh A, Behmanesh M, Aslankoohi E, Alimoghadam K, Ghaffari SH (2010) The detection of disseminated tumor cells in bone marrow and peripheral blood of gastric cancer patients by multimarker (CEA, CK20, TFF1 and MUC2) quantitative real-time PCR. Clin Biochem. doi:10.1016/j.clinbiochem.2010.11.005 PubMed

214.

Shen C, Hu L, Xia L, Li Y (2009) The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem 42(3):194–200. doi:10.1016/j.clinbiochem.2008.10.016 PubMedCrossRef

215.

Raynor MP, Stephenson SA, Pittman KB, Walsh DC, Henderson MA, Dobrovic A (2009) Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. J Hematol Oncol 2:24. doi:10.1186/1756-8722-2-24 PubMedPubMedCentralCrossRef

216.

Gkalpakiotis S, Arenberger P, Kremen J, Arenbergerova M (2010) Quantitative detection of melanoma-associated antigens by multimarker real-time RT-PCR for molecular staging: results of a 5 years study. Exp Dermatol. doi:10.1111/j.1600-0625.2010.01123.x PubMed

217.

Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R (2010) Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer 10:666. doi:10.1186/1471-2407-10-666 PubMedPubMedCentralCrossRef

218.

Mostert B, Kraan J, Sieuwerts AM, Spoel PV, Vries JB, Prager-van der Smissen WJ, Smid M, Timmermans AM, Martens JW, Gratama JW, Foekens JA, Sleijfer S (2011) CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett. doi:10.1016/j.canlet.2011.12.031 PubMed

219.

Strati A, Markou A, Parisi C, Politaki E, Mavroudis D, Georgoulias V, Lianidou E (2011) Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 11:422. doi:10.1186/1471-2407-11-422 PubMedPubMedCentralCrossRef

220.

Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmuller G (1991) Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 51(17):4712–4715PubMed

221.

Zia A, Schildberg FW, Funke I (2001) MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients. Int J Cancer 93(4):566–570PubMedCrossRef

222.

Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW (1995) Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1(10):1035–1039PubMedCrossRef

223.

Pierga JY, Bonneton C, Magdelenat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP, de Cremoux P (2005) Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 114(2):291–298. doi:10.1002/ijc.20698 PubMedCrossRef

224.

Thomas C, Wiesner C, Melchior SW, Schmidt F, Gillitzer R, Thuroff JW, Pfitzenmaier J (2009) Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. BJU Int 104(1):29–34. doi:10.1111/j.1464-410X.2008.08298.x PubMedCrossRef

225.

Indira Chandran V, Eppenberger-Castori S, Venkatesh T, Vine KL, Ranson M (2015) HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. Oncoscience 2(3):207–224PubMedCrossRef

226.

Passlick B, Izbicki JR, Simmel S, Kubuschok B, Karg O, Habekost M, Thetter O, Schweiberer L, Pantel K (1994) Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer 30a(3):376–381 (Oxford, England: 1990) PubMedCrossRef

227.

Tsujisaki M, Imai K, Hirata H, Hanzawa Y, Masuya J, Nakano T, Sugiyama T, Matsui M, Hinoda Y, Yachi A (1991) Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol 85(1):3–8PubMedPubMedCentralCrossRef

228.

Passlick B, Pantel K, Kubuschok B, Angstwurm M, Neher A, Thetter O, Schweiberer L, Izbicki JR (1996) Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. Eur J Cancer 32a(1):141–145 (Oxford, England: 1990) PubMedCrossRef

229.

Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, Ellis WJ, True LD, Young JM, Hsu L, Trask BJ, Vessella RL (2008) Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 68(14):5599–5608. doi:10.1158/0008-5472.can-08-0812 PubMedPubMedCentralCrossRef

230.

Mathiesen RR, Fjelldal R, Liestol K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, Mauermann O, Nilsen G, Christian Lingjaerde O, Borresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO (2011) High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer. doi:10.1002/ijc.26444 PubMed

231.

Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M (2011) Tumour evolution inferred by single-cell sequencing. Nature 472(7341):90–94. doi:10.1038/nature09807 PubMedPubMedCentralCrossRef

232.

Moller EK, Kumar P, Voet T, Peterson A, Van Loo P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, Naume B, Borresen-Dale AL, White KP, Nord S, Kristensen VN (2013) Next-generation sequencing of disseminated tumor cells. Front Oncol 3:320. doi:10.3389/fonc.2013.00320 PubMedPubMedCentralCrossRef

233.

Dontu G, El-Ashry D, Wicha MS (2004) Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15(5):193–197. doi:10.1016/j.tem.2004.05.011 PubMedCrossRef

234.

Rack B, Bock C, Andergassen U, Doisneau-Sixou S (2012) Hormone receptor status, erbB2 expression and cancer stem cell characteristics of circulating tumor cells in breast cancer patients. Histol Histopathol 27(7):855–864PubMed

235.

Li BD, Byskosh A, Molteni A, Duda RB (1994) Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 57(2):71–77PubMedCrossRef

236.

Brennan MJ, Donegan WL, Appleby DE (1979) The variability of estrogen receptors in metastatic breast cancer. Am J Surg 137(2):260–262PubMedCrossRef

237.

Holdaway IM, Bowditch JV (1983) Variation in receptor status between primary and metastatic breast cancer. Cancer 52(3):479–485PubMedCrossRef

238.

Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D (2010) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21(6):1254–1261. doi:10.1093/annonc/mdp427 PubMedCrossRef

239.

Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20(12):1953–1958. doi:10.1093/annonc/mdp263 PubMedPubMedCentralCrossRef

240.

Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V (2013) Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol 24(1):101–108. doi:10.1093/annonc/mds248 PubMedCrossRef

241.

Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30(21):2601–2608. doi:10.1200/JCO.2011.37.2482 PubMedCrossRef

242.

Criscitiello C, Andre F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G (2014) Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res 16(2):205PubMedPubMedCentralCrossRef

243.

Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM (2012) Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 38(6):708–714. doi:10.1016/j.ctrv.2011.11.006 PubMedCrossRef

244.

Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N (2011) Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol 9:131. doi:10.1186/1477-7819-9-131 PubMedPubMedCentralCrossRef

245.

Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S (2009) Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11(4):R59. doi:10.1186/bcr2349 PubMedPubMedCentralCrossRef

246.

Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115(3):581–590. doi:10.1007/s10549-008-0143-x PubMedCrossRef

247.

Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodriguez M, Garcia-Puche JL, Macia M, Corominas JM, Delgado-Rodriguez M, Gonzalez L, Albanell J, Fernandez M, Sole F, Lorente JA, Serrano MJ (2012) Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res 14(3):R71. doi:10.1186/bcr3180 PubMedPubMedCentralCrossRef

248.

Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, Neubauer H, Seeger H, Staebler A, Wallwiener D, Becker S (2008) ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 10(5):R76. doi:10.1186/bcr2143 PubMedPubMedCentralCrossRef

249.

Ditsch N, Mayer B, Rolle M, Untch M, Schildberg FW, Funke I (2003) Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients. Recent Results Cancer Res 162:141–147PubMedCrossRef

250.

Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME et al (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150(3):534–544. doi:10.1002/jcp.1041500314 PubMedCrossRef

251.

Platet N, Prevostel C, Derocq D, Joubert D, Rochefort H, Garcia M (1998) Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. Int J Cancer 75(5):750–756. doi:10.1002/(SICI)1097-0215(19980302) PubMedCrossRef

252.

Luqmani YA, Al Azmi A, Al Bader M, Abraham G, El Zawahri M (2009) Modification of gene expression induced by siRNA targeting of estrogen receptor alpha in MCF7 human breast cancer cells. Int J Oncol 34(1):231–242PubMed

253.

Al Saleh S, Al Mulla F, Luqmani YA (2011) Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. PLoS One 6(6):e20610. doi:10.1371/journal.pone.0020610 PubMedPubMedCentralCrossRef

254.

Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, White BA (2012) Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 132(1):75–85. doi:10.1007/s10549-011-1534-y PubMedCrossRef

255.

Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 67(13):6477–6483. doi:10.1158/0008-5472.CAN-07-0746 PubMedCrossRef

256.

Hugo HJ, Pereira L, Suryadinata R, Drabsch Y, Gonda TJ, Gunasinghe NP, Pinto C, Soo ET, van Denderen BJ, Hill P, Ramsay RG, Sarcevic B, Newgreen DF, Thompson EW (2013) Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells. Breast Cancer Res 15(6):R113. doi:10.1186/bcr3580 PubMedPubMedCentralCrossRef

257.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.1056/NEJM200103153441101 PubMedCrossRef

258.

Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C (2004) HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90(12):2344–2348. doi:10.1038/sj.bjc.6601881 PubMedPubMedCentral

259.

Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R (2015) Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials. Oncol. doi:10.1634/theoncologist.2014-0334

260.

Dang C, Iyengar N, Datko F, D’Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C (2015) Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33(5):442–447. doi:10.1200/JCO.2014.57.1745 PubMedCrossRef

261.

Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Lohberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 124(2):403–412. doi:10.1007/s10549-010-1163-x PubMedCrossRef

262.

Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D (2007) Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 18(5):851–858PubMedCrossRef

263.

Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358(13):1409–1411. doi:10.1056/NEJMc0801440 PubMedCrossRef

264.

Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16(9):2634–2645. doi:10.1158/1078-0432.CCR-09-2042 PubMedCrossRef

265.

Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart M, Sotiriou C (2011) HER2-positive circulating tumor cells in breast cancer. PLoS One 6(1):e15624. doi:10.1371/journal.pone.0015624 PubMedPubMedCentralCrossRef

266.

Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, Brandt B (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12(6):1715–1720PubMedCrossRef

267.

Wasserman L, Dreilinger A, Easter D, Wallace A (1999) A seminested RT-PCR assay for HER2/neu: initial validation of a new method for the detection of disseminated breast cancer cells. Mol Diagn 4(1):21–28. doi:10.154/modi00400021 PubMedCrossRef

268.

Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT (2010) Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 10(5):392–397. doi:10.3816/CBC.2010.n.052 PubMedCrossRef

269.

Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT (2011) Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol. doi:10.1007/s10147-011-0260-0

270.

Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85(17):1419–1424PubMedCrossRef

271.

Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K (2001) ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61(5):1890–1895PubMed

272.

Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V (2004) Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 10(24):8185–8194. doi:10.1158/1078-0432.CCR-03-0094 PubMedCrossRef

273.

Goubran HA, Stakiw J, Radosevic M, Burnouf T (2014) Platelet-cancer interactions. Semin Thromb Hemost 40(3):296–305. doi:10.1055/s-0034-1370767 PubMedCrossRef

274.

Jurasz P, Alonso-Escolano D, Radomski MW (2004) Platelet–cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 143(7):819–826. doi:10.1038/sj.bjp.0706013 PubMedPubMedCentralCrossRef

275.

Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105(1):178–185. doi:10.1182/blood-2004-06-2272 PubMedCrossRef

276.

Kopp HG, Placke T, Salih HR (2009) Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 69(19):7775–7783. doi:10.1158/0008-5472.CAN-09-2123 PubMedCrossRef

277.

Philippe C, Philippe B, Fouqueray B, Perez J, Lebret M, Baud L (1993) Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol 143(6):1713–1723PubMedPubMedCentral

278.

Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61(1):46–52PubMedPubMedCentralCrossRef

279.

Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5):576–590. doi:10.1016/j.ccr.2011.09.009 PubMedPubMedCentralCrossRef

280.

O’Flaherty JD, Gray S, Richard D, Fennell D, O’Leary JJ, Blackhall FH, O’Byrne KJ (2012) Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 76(1):19–25. doi:10.1016/j.lungcan.2011.10.018 PubMedCrossRef

281.

Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(14 Pt 1):4218–4224PubMedCrossRef

282.

Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Dieras V, Rolland E, Mignot L, Mathiot C, Bidard FC (2012) High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 23(3):618–624. doi:10.1093/annonc/mdr263 PubMedCrossRef

283.

Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel K, Janni W (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. doi:10.1093/jnci/dju066 PubMedPubMedCentral

284.

Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, Liu J, Klaus P (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. doi:10.1158/1078-0432.CCR-12-1587

285.

Camara O, Rengsberger M, Egbe A, Koch A, Gajda M, Hammer U, Jorke C, Rabenstein C, Untch M, Pachmann K (2007) The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 18(9):1484–1492PubMedCrossRef

286.

Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11(10):3678–3685PubMedCrossRef

287.

Placke T, Oergel M, Schaller M, Jung G, Rammensee HG, Kopp HG, Salih HR (2011) Platelet-derived MHC Class I confers a pseudo- normal phenotype to cancer cells that subverts the anti-tumor reactivity of natural killer immune cells. Cancer Res. doi:10.1158/0008-5472.CAN-11-1872 PubMed

288.

Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML (2006) Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 177(3):1526–1533PubMedCrossRef

289.

Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15(3):195–206. doi:10.1016/j.ccr.2009.01.023 PubMedCrossRef

290.

Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z (2001) Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 7(12):4080–4085PubMed

291.

Liotta LA, Saidel MG, Kleinerman J (1976) The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 36(3):889–894PubMed

292.

Glaves D (1983) Correlation between circulating cancer cells and incidence of metastases. Br J Cancer 48(5):665–673PubMedPubMedCentralCrossRef

293.

Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P (2012) Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol 9(1):016001. doi:10.1088/1478-3975/9/1/016001 PubMedPubMedCentralCrossRef

294.

Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30(5):525–532. doi:10.1200/JCO.2010.33.3716 PubMedCrossRef

295.

Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C (2012) Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 7(2):306–315. doi:10.1097/JTO.0b013e31823c5c16 PubMedCrossRef

296.

Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber DA, Maheswaran S (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158(5):1110–1122. doi:10.1016/j.cell.2014.07.013 PubMedPubMedCentralCrossRef

297.

Khoo BL, Lee SC, Kumar P, Tan TZ, Warkiani ME, Ow SG, Nandi S, Lim CT, Thiery JP (2015) Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget 6(17):15578–15593PubMedPubMedCentralCrossRef

298.

Alunni-Fabbroni M, Sandri MT (2010) Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods. doi:10.1016/j.ymeth.2010.01.027 PubMed

299.

Fehm T, Muller V, Alix-Panabieres C, Pantel K (2008) Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res 10(Suppl 1):S1PubMedPubMedCentralCrossRef

300.

Jacob K, Sollier C, Jabado N (2007) Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics 4(6):741–756PubMedCrossRef

301.

Lianidou ES, Markou A (2011) Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem 57(9):1242–1255. doi:10.1373/clinchem.2011.165068 PubMedCrossRef

At a glance: The STEP trials

Springer Medicine

Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding

Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models

Endoscopy-guided orthotopic implantation of colorectal cancer cells results in metastatic colorectal cancer in mice

Soft tissue invasion of papillary thyroid carcinoma

Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer